Zevra Therapeutics Inc. (ZVRA) - Total Liabilities
Based on the latest financial reports, Zevra Therapeutics Inc. (ZVRA) has total liabilities worth $136.95 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Zevra Therapeutics Inc. growing its equity to track the company's year-over-year net asset growth rate.
Zevra Therapeutics Inc. - Total Liabilities Trend (2012–2024)
This chart illustrates how Zevra Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Zevra Therapeutics Inc. generate to measure how efficiently the company converts operating cash flow to free cash.
Zevra Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Zevra Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hainan Shuangcheng Pharmaceut
SHE:002693
|
China | CN¥396.21 Million |
|
Jiangsu Feymer Technology Co Ltd
SHG:688350
|
China | CN¥1.24 Billion |
|
Farmacias Benavides S.A.B. de C.V.
MX:BEVIDESB
|
Mexico | MX$5.49 Billion |
|
Dream Finders Homes Inc
NYSE:DFH
|
USA | $2.38 Billion |
|
Hume Industries Berhad
KLSE:5000
|
Malaysia | RM424.37 Million |
|
Capex S.A
BA:CAPX
|
Argentina | AR$925.69 Billion |
|
UPC Technology Corp
TW:1313
|
Taiwan | NT$25.50 Billion |
|
Veradigm Inc.
NASDAQ:MDRX
|
USA | $513.64 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Zevra Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ZVRA stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zevra Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zevra Therapeutics Inc. (2012–2024)
The table below shows the annual total liabilities of Zevra Therapeutics Inc. from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $138.46 Million | +25.35% |
| 2023-12-31 | $110.46 Million | +174.65% |
| 2022-12-31 | $40.22 Million | +590.71% |
| 2021-12-31 | $5.82 Million | -92.50% |
| 2020-12-31 | $77.62 Million | -8.64% |
| 2019-12-31 | $84.96 Million | -8.95% |
| 2018-12-31 | $93.31 Million | -15.15% |
| 2017-12-31 | $109.97 Million | +6.17% |
| 2016-12-31 | $103.58 Million | +57.32% |
| 2015-12-31 | $65.84 Million | +73.20% |
| 2014-12-31 | $38.02 Million | +42.40% |
| 2013-12-31 | $26.70 Million | +650.04% |
| 2012-12-31 | $3.56 Million | -- |
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more